Pfizer plans another $1.5B in cuts, biotech launches with aim to shed fat (but not muscle), Otsuka ditches an Alzheimer's med, and Novo Nordisk is on fire (again).
AstraZeneca sets $80B by 2023 sales targets, two antibody fundraises totalling $345M, and Eli Lilly gets deeper into radiopharma while Astellas gets into automated cell therapy manufacturing.
Cell therapy history was made, FDA approves first two Eylea biosimilars, Gilead's $4.3B liver disease bet yields positive ph3 data, and a trilogy of lung disease positive trial data.
Bayers posts hot menopause clinical trial results, Moderna wins a major lawsuit against Pfizer-BioNTech, and a molecular glue biotech unsticks some staff
BMS lands new CAR-T accelerated approval, Roche's $2.7B obesity bet has early win, Eli Lilly leads in revenue growth, and J&J pays $850M for atopic dermatitis biotech.
A "Uniquity" good company launch, Eisai is aiming for 13-fold sales growth, and massive tariffs on imported Chinese medical supplies
Novo Nordisk's winning streak continues, Sands Capital closes a $500M+ life science fund, and a Harvard start-up lands 3 big pharma partners.
All your Biotech & Pharma news in one daily email
(Usually) All your Biotech & Pharma news in one daily email
